[go: up one dir, main page]

CA3266104A1 - Compositions and methods for delivery of rna - Google Patents

Compositions and methods for delivery of rna

Info

Publication number
CA3266104A1
CA3266104A1 CA3266104A CA3266104A CA3266104A1 CA 3266104 A1 CA3266104 A1 CA 3266104A1 CA 3266104 A CA3266104 A CA 3266104A CA 3266104 A CA3266104 A CA 3266104A CA 3266104 A1 CA3266104 A1 CA 3266104A1
Authority
CA
Canada
Prior art keywords
rna
delivery
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3266104A
Other languages
French (fr)
Inventor
John Ramunas
Glenn Jeremy Markov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rejuvenation Technologies Inc
Original Assignee
Rejuvenation Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rejuvenation Technologies Inc filed Critical Rejuvenation Technologies Inc
Publication of CA3266104A1 publication Critical patent/CA3266104A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091Purification or manufacturing processes for gene therapy compositions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3266104A 2022-08-30 2023-08-29 Compositions and methods for delivery of rna Pending CA3266104A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263402195P 2022-08-30 2022-08-30
PCT/US2023/073104 WO2024050372A2 (en) 2022-08-30 2023-08-29 Compositions and methods for delivery of rna

Publications (1)

Publication Number Publication Date
CA3266104A1 true CA3266104A1 (en) 2024-03-07

Family

ID=90098696

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3266104A Pending CA3266104A1 (en) 2022-08-30 2023-08-29 Compositions and methods for delivery of rna

Country Status (7)

Country Link
EP (1) EP4580609A2 (en)
JP (1) JP2025529173A (en)
CN (1) CN119789852A (en)
AU (1) AU2023334154A1 (en)
CA (1) CA3266104A1 (en)
IL (1) IL319195A (en)
WO (1) WO2024050372A2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022173531A1 (en) * 2021-02-10 2022-08-18 Oncorus, Inc. Compounds, compositions, and methods of using thereof

Also Published As

Publication number Publication date
IL319195A (en) 2025-04-01
EP4580609A2 (en) 2025-07-09
CN119789852A (en) 2025-04-08
WO2024050372A2 (en) 2024-03-07
JP2025529173A (en) 2025-09-04
AU2023334154A1 (en) 2025-03-06
WO2024050372A3 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
GB2605312B (en) Compositions and methods for delivery of RNA
GB2613225B (en) Compositions and methods for targeted RNA delivery
CA3249292A1 (en) Compositions and methods for delivery of nucleic acids
IL304123A (en) Compositions and methods for delivery of rna
EP4117684A4 (en) Compositions and methods for enhanced delivery of antiviral agents
EP4240248A4 (en) Compositions and methods for targeted delivery of therapeutics using carriers
IL316504A (en) Rna compositions for delivery of monkeypox antigens and related methods
AU2021413753A9 (en) Compositions and methods for delivery of rna
EP3788141A4 (en) Compositions and therapeutic methods of microrna gene delivery
EP4415690A4 (en) Compositions and methods for delivery of agents
IL288542A (en) Methods and compositions for microbial delivery of double stranded rna
CA3266104A1 (en) Compositions and methods for delivery of rna
HK40101750A (en) Compositions and methods for delivery of rna
HK40099690A (en) Compositions and methods for delivery of rna
CA3256767A1 (en) Gene therapy compositions and methods of use thereof
IL318499A (en) Compositions for targeted lysosomal degradaton and methods of use thereof
IL316049A (en) Pharmaceutical compositions of mosunetuzumab and methods of use
EP4352218A4 (en) Compositions and methods for targeted delivery of therapeutic agents
GB202319290D0 (en) Compositions and methods of gene expression
GB202319294D0 (en) Compositions and methods of gene expression
HK40112368A (en) Compositions and methods for targeted rna delivery
CA3265882A1 (en) Methods and compositions for hydrodynamic gene delivery
AU2024299365A1 (en) Compositions for delivery of plasmodium antigens and related methods
AU2024301077A1 (en) Compositions for delivery of plasmodium antigens and related methods
HK40103646A (en) Compositions for and methods of improving gene therapy